Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke

References

• World Health Organization. Risks to health. In: The World Health Report 2002. World Health Organization, Geneva, Switzerland (2002).
   Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective studies collaboration: age specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1912 (2002).
   PubMed Web of Science ®Google Scholar
• Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA275, 1557–1562 (1996).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham Study. N. Engl. J. Med.287, 781–787 (1972).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch. Intern. Med.156, 1789–1796 (1996).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Larson MG, Leip EP et al. Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation106, 3068–3072 (2002).
   PubMed Web of Science ®Google Scholar
• Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. Am. J. Coll. Cardiol.32(Suppl. A), A6–A13 (1993).
   Google Scholar
• McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N. Engl. J. Med.285, 1441–1446 (1971).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet338, 1281–1285 (1991).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Davis BR, Cutler J et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA278, 212–216 (1997).
   PubMed Web of Science ®Google Scholar
• O’Malley K, McCormack P, O’Brien ET. Isolated systolic hypertension: data from the European Working party on High Blood Pressure in the Elderly. J. Hypertens.6, S105–S108 (1988).
   PubMed Web of Science ®Google Scholar
• Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ293, 1145–1151 (1986).
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Daubert JC, Erdmann E et al. Cardiac Resynchronization-Heart Failure (CARE-HF) study investitagtors. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352, 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke22, 312–318 (1991).
   PubMed Web of Science ®Google Scholar
• Seshadri S, Beiser A, Kelly-Hayes M et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke37, 345–350 (2006).
   PubMed Web of Science ®Google Scholar
• Stergiopulos N, Westerhof N. Determinants of pulse pressure. Hypertension32, 256–559 (1998).
   Google Scholar
• Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest.56, 56–64 (1975).
   PubMed Web of Science ®Google Scholar
• Hood WP, Rackley CE, Rolett EL. Wall stress in the normal and hypertrophied human left ventricle. Am. J. Cardiol.22, 550–558 (1968).
   PubMed Web of Science ®Google Scholar
• Koren MJ, Devereux RB, Casale PN. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med.114, 345–352 (1991).
   PubMed Web of Science ®Google Scholar
• Meerson FZ. On the mechanism of compensatory hyperfunction and insufficiency of the heart. Cor. Vasa.3, 161–177 (1961).
   PubMedGoogle Scholar
• Esposito G, Rapacciuolo A, Naga Prasad SV et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation105, 85–92 (2002).
   PubMed Web of Science ®Google Scholar
• Perrino C, Naga Prasad SV, Mao L et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest.116, 1547–1560 (2006).
   PubMed Web of Science ®Google Scholar
• Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart; a new therapeutic target? Circulation109, 1580–1589 (2004).
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol. Dial. Transplant.21, 20–23 (2006).
   PubMed Web of Science ®Google Scholar
• Diez J, Querejeta R, Lopez B, Arantxa G, Mariano L, Ubago M. Losartan dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation105, 2512–2517 (2002).
   PubMed Web of Science ®Google Scholar
• Scheuer J, Buttrick P. The cardiac hypertrophy responses to pathological and physiological loads. Circulation75, 63–68 (1987).
   PubMedGoogle Scholar
• Hamasaki S, Al Suwaidi J, Higano ST, Miyauchi K, Holmes DR, Lerman A. Attenuated coronary flow reserve in patients with hypertension and left ventricular hypertrophy. J. Am. Coll. Cardiol.35, 1645–1660 (2000).
   Google Scholar
• Scheuer J, Malhotra A, Hirsch C, Capasso J, Schaible TF. Physiological cardiac hypertrophy corrects protein abnormalities associated with pathological hypertrophy in rats. J. Clin. Invest.70, 1300–1305 (1982).
   PubMed Web of Science ®Google Scholar
• Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and non-failing human heart. Circ. Res.86, 386–390 (2000).
   PubMed Web of Science ®Google Scholar
• Calderone A, Takashashi N, Izzo NJ Jr, Thaik CM, Colucci WS. Pressure and volume induced left ventricular hypertrophies are associated with distinct myocytes phenotypes and differential induction of peptide growth factor mRNAs. Circulation92, 2385–2390 (1995).
   PubMed Web of Science ®Google Scholar
• Hill JA, Olson EN. Cardiac plasticity. N. Engl. J. Med.358, 1370–1380 (2008).
   PubMed Web of Science ®Google Scholar
• Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: aging arteries: a “set up” for vascular disease. Circulation103, 139 (2003).
   Google Scholar
• Clement DL, De Buyzere ML, De Bacquer DA et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N. Engl. J. Med.348, 2407–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Meani S, Salerno M. Cardiovascular target organ damage in essential hypertension with or without reproducible nocturnal fall in blood pressure. J. Hypertens.22, 273–280 (2004).
   PubMed Web of Science ®Google Scholar
• Goyal D, MacFadyen RJ, Watson RD, Lip GY. Ambulatory blood pressure monitoring in heart failure; a systematic review. Eur. J. Heart Fail.7, 149–156 (2005).
   PubMed Web of Science ®Google Scholar
• Lee KW, Blann AD, Lip GY. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am. J. Hypertens.18, 104–115 (2005).
   PubMed Web of Science ®Google Scholar
• Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension46, 185–193 (2005).
   PubMed Web of Science ®Google Scholar
• Sugden PH. Mechanotransduction in cardiomyocytes hypertrophy. Circulation103, 1375–1377 (2001).
   PubMed Web of Science ®Google Scholar
• Baines CP, Molkentin JD. Stress signalling pathways that modulate cardiac myocytes apoptosis. J. Mol. Cell Cardiol.38, 47–62 (2005).
   PubMed Web of Science ®Google Scholar
• Banfi C, Cavalca V, Veglia F et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur. Heart J.26, 481–488 (2005).
   PubMedGoogle Scholar
• Yang DK, Choi BY, Lee YH et al. Gene profiling during regression of pressure overload-induced cardiac hypertrophy. Physiol. Genom.30, 1–7 (2007).
   PubMed Web of Science ®Google Scholar
• Stansfield WE, Tang RH, Moss NC, Baldwin AS, Willis MS, Selzman CH. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am. J. Physiol. Heart Circ. Physiol.294, H645–H650 (2008).
   Google Scholar
• Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography: anatomic validation, standardisation and comparison to other methods. Hypertenison9, 119–126 (1987).
   Google Scholar
• Opie LH, Commerford PJ, Gersh B, Pfeffer MA. Controversies in ventricular remodeling. Lancet367, 356–367 (2006).
   PubMed Web of Science ®Google Scholar
• Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J. Am. Coll. Cardiol.19, 1550–1558 (1992).
   PubMed Web of Science ®Google Scholar
• Segers P, Stergiopulos N, Westerhof N. Quantification of the contribution of cardiac and arterial remodeling to hypertension. Hypertension36, 760–765 (2000).
   PubMed Web of Science ®Google Scholar
• Gerdts E. Left ventricular structure in different types of chronic pressure overload. Eur. Heart J.10, E23–E30 (2008).
   Google Scholar
• Grosse P, Jullien V, Jarnier P, Lemetayer P, Clementy J. Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of text ventricular mass? J. Hum. Hypertens.13, 505–509 (1999).
   PubMed Web of Science ®Google Scholar
• Huber D, Grimm J, Koch R, Krayenbuehl HP. Determinants of ejection performance in aortic stenosis. Circulation64, 126–134 (1981).
   PubMed Web of Science ®Google Scholar
• Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz27, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J. Am. Coll. Cardiol.48, 89–96 (2006).
   PubMed Web of Science ®Google Scholar
• Kim S, Ohta K, Hamaguchi A et al. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J. Pharmacol. Exp. Ther.273, 509–515 (1995).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Roman MJ, Paranicas M et al. A population based assessment of left ventricular systolic dysfunction in middle aged and older adults: the Strong Heart Study. Am. Heart J.141, 436–446 (2001).
   Google Scholar
• Devereux RB, Bella JN, Palmieri V et al. Left ventricular systolic dysfunction in a biracial sample of hypertensive adults: the Hypertension Genetic Epidemiology Network (HyperGEN) study. Hypertension38, 417–423 (2001).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Rokkedal J, Bella JN et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE Study). Am. J. Cardiol.87, 54–60 (2001).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of risk of coronary heart disease. The Framingham Study. Ann. Intern. Med.72, 813–822 (1970).
   PubMedGoogle Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med.322, 1561–1566 (1990).
   PubMed Web of Science ®Google Scholar
• Drazner MH, Rame JE, Marino EK et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction: the Cardiovascular Health Study. J. Am. Coll. Cardiol.43, 2207–2215 (2004).
   PubMed Web of Science ®Google Scholar
• Tsang TS, Barnes ME, Gersh BJ et al. Prediction of risk for first age related cardiovascular events in an elderly population: the incremental value of echocardiography. J. Am. Coll. Cardiol.42, 1199–1205 (2003).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C et al. Prognostic value of left ventricular mass and geometry in systemic hypertension n with left ventricular hypertrophy. Am. J. Cardiol.78, 197–202 (1996).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA292, 2350–2356 (2004).
   PubMed Web of Science ®Google Scholar
• Palmieri V, Dahlof B, DeQuattro V et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J. Am. Coll. Cardiol.34, 1625–1632 (1999).
   PubMed Web of Science ®Google Scholar
• Agabiti-Rosei E, Muiesan ML, Salvetti M. New approaches in the assessment of left ventricular hypertrophy. Ther. Adv. Cardiovasc. Dis.1, 119–128 (2007).
   PubMedGoogle Scholar
• Bluemke DA, Kronmal RA, Joao AC et al. The relationship of left ventricular mass and geometry to incident cardiovascular events. The MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol.52, 2148–2155 (2008).
   PubMed Web of Science ®Google Scholar
• Cerrato P, Grasso M, Imperiale D. Stroke in young patients: etiopathogenesis and risk factors in different age classes. Cerebrovasc. Dis.18, 154–159 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenblum WI. Millary aneurisms and “fibrinoid” degeneration of cerebral blood vessels. Hum. Pathol.8, 133–139 (1997).
   Google Scholar
• Miyao S, Takano A, Teramoto J, Takashashi A. Leukoaraiosis in relation to prognosis for patients with lacunar infarction. Stroke23, 1434–1438 (1992).
   PubMed Web of Science ®Google Scholar
• Kuo HK, Lipsitz LA. Cerebral white matter changes and geriatric syndromes: is there a link? J. Gerontol. A Biol. Sci. Med. Sci.59, 818–826 (2004).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral haemorrhage. N. Engl. J. Med.344, 1450–1460 (2001).
   PubMed Web of Science ®Google Scholar
• Welin L, Svardsudd K, Wilhelmesen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N. Engl. J. Med.317, 521–526 (1987).
   PubMed Web of Science ®Google Scholar
• Bikkina M, Levy D, Evans JC et al. Left ventricular mass and risk of stroke in an elderly cohort: the Framingham Heart Study. JAMA272, 33–36 (1994).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Pickering TG, Harshfield GA et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation68, 470–476 (1983).
   PubMed Web of Science ®Google Scholar
• Longstreth WT, Manolio TA, Arnold A et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke27, 2043–2047 (1996).
   PubMed Web of Science ®Google Scholar
• Sierra C, De La Sierra A, Pare JC, Gomez-Angelats E, Coca A. Correlation between silent cerebral white mater lesions and left ventricular mass and geometry in essential hypertension. Am. J. Hypertens.15, 507–512 (2002).
   PubMed Web of Science ®Google Scholar
• Selvetella G, Notte A, Maffei A et al. Left ventricular hypertrophy is associated with asymptomatic cerebral damage in hypertensive patients. Stroke34, 1766–1770 (2003).
   PubMed Web of Science ®Google Scholar
• Di Tullio MR, Zwas DR, Sacco RL, Sciacca RR, Homma S. Left ventricular mass and geometry and risk of ischemic stroke. Stroke34, 2380–2386 (2003).
   PubMed Web of Science ®Google Scholar
• Ganau A, Saba PS, Roman MJ, De Simone G, Realdi G, Devereux RB. Ageing induces left ventricular concentric remodelling in normotensive subjects. J. Hypertens.13, 1818–1822 (1995).
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Lonati L, Sampieri L et al. Left ventricular concentric remodeling and carotid structural changes in essential hypertension. J. Hypertens.14, 1441–1446 (1996).
   PubMed Web of Science ®Google Scholar
• Manios E, Tsivgoulis G, Koroboki E et al. Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke40, 1515–1518 (2009).
   PubMed Web of Science ®Google Scholar
• Drukteinis JS, Roman MJ, Fabsitz RR, Lee ET, Best LG, Russell M. Cardiac and systematic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults – the Strong Heart Study. Circulation115, 221–227 (2007).
   PubMed Web of Science ®Google Scholar
• Devereaux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation88, 1444–1455 (1993).
   PubMed Web of Science ®Google Scholar
• Mehta SK, Rame E, Khera A et al. Left ventricular hypertrophy, subclinical atherosclerosis and inflammation. Hypertension49, 1385–1391 (2007).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. Am. J. Cardiol.82, N2–N9 (1998).
   PubMed Web of Science ®Google Scholar
• Tsang TS, Gersh BJ, Appleton CP et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J. Am. Coll. Cardiol.40, 1636–1644 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes M, Lip GY. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation; a systematic review of stroke risk factors, risk stratification scheme and cost effectiveness data. J. Thromb. Haemost.99, 295–304 (2008).
   Google Scholar
• Gladstone DJ, Blakely J, Dorian P et al. EMBRACE pilot study group. Detecting paroxysmal atrial fibrillation after ischemic stroke and transient ischemic attack: if you don’t look, you won’t find. Stroke39, E78–E79 (2008).
   Google Scholar
• Wachtell K, Devereux RB, Lyle PA, Okin PM, Gerdts E. The left atrium, atrial fibrillation and the risk of stroke in hypertensive patients with left ventricular hypertrophy. Ther. Adv. Cardiovasc. Dis.2, 507–513 (2008).
   PubMedGoogle Scholar
• Lip GYH. Hypertension, platelets and the endothelium; the “Thrombotic Paradox” of hypertension (or Birmingham paradox) revisited. Hypertension41, 199–200 (2003).
   PubMed Web of Science ®Google Scholar
• Lip GYH. Hypertension and the prothrombotic state. J. Hum. Hypertens.14, 687–690 (2000).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Blann AD. Does hypertension confer a prothrombotic state? Virchow’s triad revisited. Circulation101, 218–220 (2000).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J. Hum. Hypertens.8, 693–701 (1994).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am. J. Cardiol.80, 1566–1570 (1997).
   PubMed Web of Science ®Google Scholar
• Blann AD. Lip GYH. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul. Fibrinolysis9, 297–306 (1998).
   PubMed Web of Science ®Google Scholar
• Blann AD, Waite MA. Von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Cor. Art. Dis.7, 143–147 (1996).
   PubMed Web of Science ®Google Scholar
• Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. Von Willebrand factor, soluble P-selectin and target organ damage in hypertension: a substudy of the Anglo–Scandinavian Cardiac Outcomes Trials (ASCOT). Hypertension40, 61–66 (2002).
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Esposito A, Negri F et al. Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am. J. Hypertens.21, 365–366 (2008).
   PubMed Web of Science ®Google Scholar
• Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J. Am. Coll. Cardiol.27, 1214–1218 (1996).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Harris KE et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann. Intern. Med.147, 311–319 (2007).
   PubMed Web of Science ®Google Scholar
• Okin PM, Wachtell K, Devereux RB et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new onset atrial fibrillation in patients with hypertension. JAMA296, 1242–1248 (2006).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am. J. Hypertens.19, 493–499 (2006).
   PubMed Web of Science ®Google Scholar
• MacMahon SW, Wilcken DEL, McDonald GJ. The effect of weight reduction on left ventricular mass: a randomized controlled trial in young, overweight hypertensive patients. N. Engl. J. Med.314, 334–339 (1986).
   PubMed Web of Science ®Google Scholar
• Ferrara LA, DeSimone G, Pasanisi F, Mancini M, Mancini M. Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension6, 755–759 (1984).
   PubMed Web of Science ®Google Scholar
• Rodriguez CJ, Sacco RL, Sciacca RR, Boden-Albala B, Homma S, Di Tullio MR. Physical activity attenuates the effect of increased left ventricular mass on the risk of ischemic stroke: the Northern Manhattan Stroke Study. J. Am. Coll. Cardiol.39, 1482–1488 (2002).
   PubMed Web of Science ®Google Scholar
• Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA270, 713–724 (1993).
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach focus on treatment by antihypertensive agents. Am. J. Hypertens.11, 1394–1404 (1998).
   PubMed Web of Science ®Google Scholar
• Moser M, Herbert PR. Prevention of disease progression. LVH and CHF in hypertension treatment trials. J. Am. Coll. Cardiol.27, 1214–1218 (1996).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens.16, 895–899 (2003).
   PubMed Web of Science ®Google Scholar
• Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J. Hypertens.18, 1465–1475 (2000).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Gosse P, Guéret P et al. The PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J. Hypertens.23(11), 2063–2070 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Bevereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359(9311), 995–1003 (2002)
   PubMed Web of Science ®Google Scholar
• Wachtell K, Palmieri V, Olsen MH et al. Change in systolic left ventricular performance after 3 year of antihypertensive treatment; The Losartan Intervention for Endpoint (LIFE) study. Circulation106, 227–232 (2002).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F et al. Angiotension-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension46, 386–392 (2005).
   PubMed Web of Science ®Google Scholar
• Turnbull F; Blood pressure lowering treatment trialist’s collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet362, 1527–1523 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N. Engl. J. Med.358–1041 (2000).
   Google Scholar
• Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke35, 348–350 (2004).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al. MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: principal results of a prospective randomised controlled study (MOSES). Stroke36, 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359, 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J. Hypertens.26, 1282–1289 (2008).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener HC, Sacco RL et al. PRoFESS study group. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med.359, 1225–1237 (2008).
   PubMed Web of Science ®Google Scholar
• Madrid AH, Peng J, Zamora J et al. The role of angiotensin receptor blockers and or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in the patients with cardiovascular disease: meta-analysis of randomised controlled clinical trials. Pacing. Clin. Electrophysiol.27, 1405–1410 (2004).
   PubMed Web of Science ®Google Scholar